-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BioLineRx (BLRX)
-
-
-
-
-
-
-
BioLineRx (BLRX) PT Lowered to $9 at H.C. Wainwright
-
-
-
-
-
-
-
BioLineRx (BLRX) Tops Q1 EPS by 16c
-
-
-
-
-
-
-
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
-
-
-
-
-
-
-
BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

